Literature DB >> 12519059

Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.

Donald J Skalitzky1, Joseph T Marakovits, Karen A Maegley, Anne Ekker, Xiao-Hong Yu, Zdenek Hostomsky, Stephen E Webber, Brian W Eastman, Robert Almassy, Jianke Li, Nicola J Curtin, David R Newell, A Hilary Calvert, Roger J Griffin, Bernard T Golding.   

Abstract

Novel tricyclic benzimidazole carboxamide poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been synthesized. Several compounds were found to be powerful chemopotentiators of temozolomide and topotecan in both A549 and LoVo cell lines. In vitro inhibition of PARP-1 was confirmed by direct measurement of NAD+ depletion and ADP-ribose polymer formation caused by chemically induced DNA damage.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12519059     DOI： 10.1021/jm0255769

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  16 in total

1.  Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.

Authors:  Dong Zhou; Wenhua Chu; Jinbin Xu; Lynne A Jones; Xin Peng; Shihong Li; Delphine L Chen; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2014-01-24       Impact factor: 3.641

2.  Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.

Authors:  Yulia V Surovtseva; Vikram Jairam; Ahmed F Salem; Ranjini K Sundaram; Ranjit S Bindra; Seth B Herzon
Journal:  J Am Chem Soc       Date:  2016-03-09       Impact factor: 15.419

Review 3.  Harnessing synthetic lethal interactions in anticancer drug discovery.

Authors:  Denise A Chan; Amato J Giaccia
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

4.  P4O10/TfOH mediated domino condensation-cyclization of amines with diacids: a route to indolizidine alkaloids under catalyst- and solvent-free conditions.

Authors:  Ketan S Mandrekar; Santosh G Tilve
Journal:  RSC Adv       Date:  2022-06-15       Impact factor: 4.036

Review 5.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 6.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 7.  Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Authors:  Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

8.  INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.

Authors:  Kathryn A Mason; David Valdecanas; Nancy R Hunter; Luka Milas
Journal:  Invest New Drugs       Date:  2007-07-13       Impact factor: 3.850

9.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Authors:  Wataru Sakai; Elizabeth M Swisher; Beth Y Karlan; Mukesh K Agarwal; Jake Higgins; Cynthia Friedman; Emily Villegas; Céline Jacquemont; Daniel J Farrugia; Fergus J Couch; Nicole Urban; Toshiyasu Taniguchi
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

10.  Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents.

Authors:  Dong Zhou; Huaping Chen; Cedric Mpoy; Sadia Afrin; Buck E Rogers; Joel R Garbow; John A Katzenellenbogen; Jinbin Xu
Journal:  Biomedicines       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.